Lantheus Holdings Inc (LNTH) Position Lowered by Peregrine Capital Management LLC

Peregrine Capital Management LLC decreased its stake in Lantheus Holdings Inc (NASDAQ:LNTH) by 1.5% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 567,774 shares of the medical equipment provider’s stock after selling 8,572 shares during the period. Peregrine Capital Management LLC owned approximately 1.48% of Lantheus worth $8,488,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Piedmont Investment Advisors LLC acquired a new stake in shares of Lantheus in the second quarter valued at about $104,000. Itau Unibanco Holding S.A. acquired a new stake in shares of Lantheus in the second quarter valued at about $104,000. NumerixS Investment Technologies Inc lifted its stake in shares of Lantheus by 1,000.0% in the second quarter. NumerixS Investment Technologies Inc now owns 7,700 shares of the medical equipment provider’s stock valued at $113,000 after purchasing an additional 7,000 shares during the period. Sun Life Financial INC acquired a new stake in shares of Lantheus in the second quarter valued at about $140,000. Finally, SG Americas Securities LLC acquired a new stake in shares of Lantheus in the second quarter valued at about $151,000. Hedge funds and other institutional investors own 92.52% of the company’s stock.

Shares of LNTH opened at $13.50 on Friday. The company has a quick ratio of 3.14, a current ratio of 3.86 and a debt-to-equity ratio of 5.94. The stock has a market cap of $517.05 million, a price-to-earnings ratio of 16.07, a price-to-earnings-growth ratio of 3.10 and a beta of 1.32. Lantheus Holdings Inc has a 12-month low of $12.80 and a 12-month high of $24.45.

Lantheus (NASDAQ:LNTH) last announced its earnings results on Wednesday, August 1st. The medical equipment provider reported $0.26 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.22 by $0.04. The company had revenue of $85.60 million during the quarter, compared to analysts’ expectations of $87.90 million. Lantheus had a net margin of 37.53% and a return on equity of 560.19%. The firm’s quarterly revenue was down 3.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.35 earnings per share. As a group, research analysts anticipate that Lantheus Holdings Inc will post 0.87 earnings per share for the current year.

Several brokerages recently commented on LNTH. BidaskClub cut shares of Lantheus from a “buy” rating to a “hold” rating in a research note on Tuesday, September 25th. ValuEngine upgraded shares of Lantheus from a “sell” rating to a “hold” rating in a research note on Monday, August 20th. Zacks Investment Research cut shares of Lantheus from a “hold” rating to a “sell” rating in a research note on Saturday, August 4th. Wells Fargo & Co reduced their price objective on shares of Lantheus from $26.00 to $20.00 and set an “outperform” rating for the company in a research note on Thursday, August 2nd. Finally, Credit Suisse Group reduced their price objective on shares of Lantheus from $23.00 to $21.00 and set a “neutral” rating for the company in a research note on Thursday, August 2nd. One analyst has rated the stock with a sell rating, three have given a hold rating and two have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $23.75.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, an ultrasound contrast agent used in ultrasound exams of the heart; TechneLite, a technetium generator that provides the essential nuclear material used in nuclear medicine procedures; and Xenon, a radiopharmaceutical gas used to assess pulmonary function and imaging cerebral blood flow.

Read More: Understanding Compound Annual Growth Rate (CAGR)

Institutional Ownership by Quarter for Lantheus (NASDAQ:LNTH)

Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply